At TZAR Labs, we're pioneering the detection of primary, secondary, and tertiary tumors by subtype. We have developed a first-of-its-kind non-invasive patented 'HrC' test (NIHT) through meticulously conducted clinical trials. HrC is a proprietary algorithm developed by our scientists from certain transcriptomic markers that we are able to get from cells isolated in peripheral blood. A simple yet effective and swift blood test has proven exceptional in detecting cancer during the early stages. This process involves the determination of harbinger cells of cancer by identifying specific markers that uniquely depict, diagnose, prognosis, and characterize cancer. As technology, science, and the course of our daily lives progress, we believe in the value of access to a blood test method of disease detection.
\